arrow
N

Nádia Emi Aikawa

Universidade de São Paulo
H指数:36
被引数:4,489

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Linear growth is independently associated with health-related quality of life during healthcare transition in youth with special health care needs

线性生长与有特殊医疗需求的青少年在医疗过渡期间的健康相关生活质量独立相关

2026-08-040
OA
Recombinant herpes zoster vaccine in patients with autoimmune rheumatic diseases in Brazil: a double-blind, randomised, placebo-controlled, phase 4, non-inferiority study

重组带状疱疹疫苗在巴西自身免疫性风湿病患者的应用:一项双盲、随机、安慰剂对照、IV期、非劣效性研究

2026-02-090
PRE
Effect of hydroxychloroquine dose reduction (2-3 mg/kg/day) on lipoprotein levels in stable lupus nephritis: A 12-month randomized controlled longitudinal study

羟氯喹剂量减少(2-3 mg/kg/天)对稳定狼疮肾炎患者脂蛋白水平的影响:一项为期12个月的随机对照纵向研究

Lupus
IF1.9
2025-12-010
PRE
Long-Term Follow-Up of Anti-Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering
2024-07-143
PRE
Food consumption based on processing level (according to Nova system) during the COVID-19 pandemic among adolescents with immunocompromised conditions: a case-control study

在新型冠状病毒肺炎大流行期间,免疫功能低下的青少年基于加工水平 (根据Nova系统) 的食物消耗: 一项病例对照研究

2023-05-161
OAAI
Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis
2023-01-0110
OAAI
Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
2022-10-036
OAAI
Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients
2022-07-263
OA
Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus
2022-03-0425
OA
Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases
2022-03-0117
OAAI
Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients
2022-03-012
OA
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
2022-02-0119
OAAI
Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases
2021-11-297
OAAI
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
2021-07-30152
OAAI
Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients
2020-12-0119
PREAI